ANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections
ANTABIO awarded up to $8.9M from CARB-X to accelerate the development of its new treatment for chronic infections in Cystic Fibrosis patients